Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-a drugs: An Italian multicenter study

Ennio Lubrano, Fabio Massimo Perrotta, Antonio Marchesoni, Salvatore D'Angelo, Roberta Ramonda, Olga Addimanda, Ignazio Olivieri, Leonardo Punzi, Carlo Salvarani

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective. To investigate the possibility of achieving partial remission (PR) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) versus ankylosing spondylitis (AS) treated with anti-tumor necrosis factor (TNF)-α antagonists, such as adalimumab (ADA), etanercept (ETN), and infliximab (IFX), in a real clinical practice setting. The Assessment of SpondyloArthritis international Society (ASAS) 20, ASAS40, and Ankylosing Spondylitis Disease Activity Score were also calculated. Methods. A retrospective study was conducted in patients with axSpA treated with ADA, ETN, and IFX from 2000 to 2013. All patients fulfilled the ASAS or the modified New York criteria. PR was reached when the score was <20 mm (on a visual analog scale of 0-100 mm) in each of these domains: (1) patient global assessment, (2) pain, (3) function, and (4) inflammation. Results. A total of 321 patients with axSpA were treated. Among them, 62 were nr-axSpA while the remaining 259 were AS. Log-rank test to compare survival curves showed that the probability of obtaining PR in nr-axSpA and AS during treatment with anti-TNF-&alpha was not significantly different. At 12 weeks of exposure to the first anti-TNF-α drug, PR was achieved in 7 patients with nr-axSpA (11.3%) and in 68 patients with AS (26.2%). Conclusion. Our results, obtained from clinical practice, showed that PR is an achievable target of anti-TNF-α treatment in nr-axSpA. The PR rate, as a reliable indicator of sustained effectiveness, is similar in nr-axSpA and in AS.

Original languageEnglish
Pages (from-to)258-263
Number of pages6
JournalJournal of Rheumatology
Volume42
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Ankylosing Spondylitis
Multicenter Studies
Tumor Necrosis Factor-alpha
Pharmaceutical Preparations
Pain Measurement
Visual Analog Scale
Retrospective Studies
Inflammation
Survival
Therapeutics

Keywords

  • Ankylosing spondylitis
  • Anti-TNF-αdrugs
  • Nonradiographic axial spondyloarthritis
  • Remission

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-a drugs : An Italian multicenter study. / Lubrano, Ennio; Perrotta, Fabio Massimo; Marchesoni, Antonio; D'Angelo, Salvatore; Ramonda, Roberta; Addimanda, Olga; Olivieri, Ignazio; Punzi, Leonardo; Salvarani, Carlo.

In: Journal of Rheumatology, Vol. 42, No. 2, 01.02.2015, p. 258-263.

Research output: Contribution to journalArticle

Lubrano, Ennio ; Perrotta, Fabio Massimo ; Marchesoni, Antonio ; D'Angelo, Salvatore ; Ramonda, Roberta ; Addimanda, Olga ; Olivieri, Ignazio ; Punzi, Leonardo ; Salvarani, Carlo. / Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-a drugs : An Italian multicenter study. In: Journal of Rheumatology. 2015 ; Vol. 42, No. 2. pp. 258-263.
@article{7ca7bbe0ec5749b69f49c0a0a46ac188,
title = "Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-a drugs: An Italian multicenter study",
abstract = "Objective. To investigate the possibility of achieving partial remission (PR) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) versus ankylosing spondylitis (AS) treated with anti-tumor necrosis factor (TNF)-α antagonists, such as adalimumab (ADA), etanercept (ETN), and infliximab (IFX), in a real clinical practice setting. The Assessment of SpondyloArthritis international Society (ASAS) 20, ASAS40, and Ankylosing Spondylitis Disease Activity Score were also calculated. Methods. A retrospective study was conducted in patients with axSpA treated with ADA, ETN, and IFX from 2000 to 2013. All patients fulfilled the ASAS or the modified New York criteria. PR was reached when the score was <20 mm (on a visual analog scale of 0-100 mm) in each of these domains: (1) patient global assessment, (2) pain, (3) function, and (4) inflammation. Results. A total of 321 patients with axSpA were treated. Among them, 62 were nr-axSpA while the remaining 259 were AS. Log-rank test to compare survival curves showed that the probability of obtaining PR in nr-axSpA and AS during treatment with anti-TNF-&alpha was not significantly different. At 12 weeks of exposure to the first anti-TNF-α drug, PR was achieved in 7 patients with nr-axSpA (11.3{\%}) and in 68 patients with AS (26.2{\%}). Conclusion. Our results, obtained from clinical practice, showed that PR is an achievable target of anti-TNF-α treatment in nr-axSpA. The PR rate, as a reliable indicator of sustained effectiveness, is similar in nr-axSpA and in AS.",
keywords = "Ankylosing spondylitis, Anti-TNF-αdrugs, Nonradiographic axial spondyloarthritis, Remission",
author = "Ennio Lubrano and Perrotta, {Fabio Massimo} and Antonio Marchesoni and Salvatore D'Angelo and Roberta Ramonda and Olga Addimanda and Ignazio Olivieri and Leonardo Punzi and Carlo Salvarani",
year = "2015",
month = "2",
day = "1",
doi = "10.3899/jrheum.140811",
language = "English",
volume = "42",
pages = "258--263",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "2",

}

TY - JOUR

T1 - Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-a drugs

T2 - An Italian multicenter study

AU - Lubrano, Ennio

AU - Perrotta, Fabio Massimo

AU - Marchesoni, Antonio

AU - D'Angelo, Salvatore

AU - Ramonda, Roberta

AU - Addimanda, Olga

AU - Olivieri, Ignazio

AU - Punzi, Leonardo

AU - Salvarani, Carlo

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Objective. To investigate the possibility of achieving partial remission (PR) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) versus ankylosing spondylitis (AS) treated with anti-tumor necrosis factor (TNF)-α antagonists, such as adalimumab (ADA), etanercept (ETN), and infliximab (IFX), in a real clinical practice setting. The Assessment of SpondyloArthritis international Society (ASAS) 20, ASAS40, and Ankylosing Spondylitis Disease Activity Score were also calculated. Methods. A retrospective study was conducted in patients with axSpA treated with ADA, ETN, and IFX from 2000 to 2013. All patients fulfilled the ASAS or the modified New York criteria. PR was reached when the score was <20 mm (on a visual analog scale of 0-100 mm) in each of these domains: (1) patient global assessment, (2) pain, (3) function, and (4) inflammation. Results. A total of 321 patients with axSpA were treated. Among them, 62 were nr-axSpA while the remaining 259 were AS. Log-rank test to compare survival curves showed that the probability of obtaining PR in nr-axSpA and AS during treatment with anti-TNF-&alpha was not significantly different. At 12 weeks of exposure to the first anti-TNF-α drug, PR was achieved in 7 patients with nr-axSpA (11.3%) and in 68 patients with AS (26.2%). Conclusion. Our results, obtained from clinical practice, showed that PR is an achievable target of anti-TNF-α treatment in nr-axSpA. The PR rate, as a reliable indicator of sustained effectiveness, is similar in nr-axSpA and in AS.

AB - Objective. To investigate the possibility of achieving partial remission (PR) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) versus ankylosing spondylitis (AS) treated with anti-tumor necrosis factor (TNF)-α antagonists, such as adalimumab (ADA), etanercept (ETN), and infliximab (IFX), in a real clinical practice setting. The Assessment of SpondyloArthritis international Society (ASAS) 20, ASAS40, and Ankylosing Spondylitis Disease Activity Score were also calculated. Methods. A retrospective study was conducted in patients with axSpA treated with ADA, ETN, and IFX from 2000 to 2013. All patients fulfilled the ASAS or the modified New York criteria. PR was reached when the score was <20 mm (on a visual analog scale of 0-100 mm) in each of these domains: (1) patient global assessment, (2) pain, (3) function, and (4) inflammation. Results. A total of 321 patients with axSpA were treated. Among them, 62 were nr-axSpA while the remaining 259 were AS. Log-rank test to compare survival curves showed that the probability of obtaining PR in nr-axSpA and AS during treatment with anti-TNF-&alpha was not significantly different. At 12 weeks of exposure to the first anti-TNF-α drug, PR was achieved in 7 patients with nr-axSpA (11.3%) and in 68 patients with AS (26.2%). Conclusion. Our results, obtained from clinical practice, showed that PR is an achievable target of anti-TNF-α treatment in nr-axSpA. The PR rate, as a reliable indicator of sustained effectiveness, is similar in nr-axSpA and in AS.

KW - Ankylosing spondylitis

KW - Anti-TNF-αdrugs

KW - Nonradiographic axial spondyloarthritis

KW - Remission

UR - http://www.scopus.com/inward/record.url?scp=84923128642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923128642&partnerID=8YFLogxK

U2 - 10.3899/jrheum.140811

DO - 10.3899/jrheum.140811

M3 - Article

C2 - 25512483

AN - SCOPUS:84923128642

VL - 42

SP - 258

EP - 263

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 2

ER -